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We have shown previously that the terminal disposition half-life of SN-38, the active metabolite of irinotecan, is much longer
than earlier thought. Currently, it is not known whether this prolonged exposure has any relevance toward SN-38-induced
toxicity. Here, we found that SN-38 concentrations present in human plasma for up to 3 weeks after a single irinotecan
infusion induce signiﬁcant cytotoxicity in vitro. Using pharmacokinetic data from 26 patients, with sampling up to 500 h,
relationships were evaluated between systemic exposure (AUC) to SN-38 and the per cent decrease in absolute neutrophil
count (ANC) at nadir, or by taking the entire time course of ANC into account (AOC). The time course of SN-38
concentrations (AUC500 h) was signiﬁcantly related to this AOC (P50.001). Based on these ﬁndings, a new limited-sampling
model was developed for SN-38 AUC500 h using only two timed samples: AUC500 h=(6.5886C2.5 h)+(146.46C49.5 h)+15.53,
where C2.5 h and C49.5 h are plasma concentrations at 2.5 and 49.5 h after start of infusion, respectively. The use of this
limited-sampling model may open up historic databases to retrospectively obtain information about SN-38-induced toxicity in
patients treated with irinotecan.
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Irinotecan (CPT-11) belongs to the family of camptothecins, and is
a member of the class of topoisomerase I inhibitors. A broad spec-
trum of anti-tumour activity was seen in preclinical models as well
as in patients, with responses observed in various disease types,
including colorectal, lung, cervical, and ovarian cancers (Mathijssen
et al, 2001; Vanhoefer et al, 2001). CPT-11 is a prodrug that
requires activation to the active metabolite, 7-ethyl-10-hydroxy-
camptothecin (SN-38), which is approximately 100- to 1000-fold
more active than the parent drug (Hertzberg et al, 1989). A host
of enzymes, including carboxylesterases to form SN-38 (Humerick-
house et al, 2000), UDP glucuronosyltransferases mediating SN-38
glucuronidation to form the b-glucuronic acid conjugate, SN-38G,
(Iyer et al, 1998), intestinal and endogenous b-glucuronidases caus-
ing deconjugation of SN-38G (Sparreboom et al, 1998; Slatter et al,
2000), as well as cytochrome P-450 isoforms (Haaz et al, 1999;
Santos et al, 2000) to form APC and NPC are involved in CPT-
11 metabolism. In addition, several drug-transporting proteins,
notably a canalicular multispeciﬁc organic anion transporter
(cMOAT) located on the bile canalicular membrane (Chu et al,
1998), and P-glycoprotein (Chu et al, 1999), can inﬂuence CPT-
11 elimination through hepatobiliary secretion and intestinal (re-
)absorption.
As a result of these (and probably also other presently unknown)
mechanisms, CPT-11 and its metabolites are subject to large inter-
individual kinetic variability (Mathijssen et al, 2002a), and show
relatively long disposition half-lives. We have recently shown that
by applying an extended sampling-time period of 500 h, the circu-
lation time of SN-38 in cancer patients was found to be
substantially longer than held previously (Kehrer et al, 2000). We
hypothesised that, because of the poorly deﬁned relationships
between pharmacokinetic parameters and pharmacodynamic
outcome of CPT-11 treatment (Mathijssen et al, 2001), the
prolonged terminal-disposition phase of SN-38 should be taken
into consideration in future studies to identify kinetic correlates
that would assist in prediction of the dose-limiting myelosuppres-
sion. Here, we examined the impact of this prolonged SN-38
exposure using an in vitro approach with a panel of human cancer
cell lines, and re-examined exposure-toxicity relationships in a
group of 26 cancer patients treated with CPT-11 administered as
a 90-min intravenous infusion in a 3-weekly regimen at a dose
of 350 mg m
72.
MATERIALS AND METHODS
Growth-inhibition studies
Exponentially growing cells obtained from the IGROV (ovarian
cancer), Caco-2 (colon cancer) and H226 (lung cancer) cell lines
were cultured in 4 ml of RPMI-1640 medium, and plated in 25
cm
2 T-ﬂasks (Corning Costar), at a density of 10000 cells/ﬂask.
Hereafter, plates were incubated in a controlled environment at
378C and 95% air per 5% CO2, and 24 h after the start of incu-
bation, the medium was replaced by medium containing SN-38
at ﬁnal concentrations of 100 pM (39.2 pg ml
71), 1.00 nM
(392 pg ml
71), or 10.0 nM (3920 pg ml
71). These concentrations
were chosen because they adequately simulated the median SN-
38 plasma concentrations circulating in patients after 3 weeks,
10 days and 2 days, respectively, after infusion of the standard
dose of CPT-11 (350 mg m
72, given as a 90-min infusion once
every 3 weeks; see Figure 1). As a control, ﬂasks containing cells
in the absence of SN-38 were used. At 48-h intervals, and for a
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medium was replaced with fresh medium to minimise possibly
confounding effects caused by instability of SN-38 through
chemical instability. At the same intervals, culture ﬂasks were
treated with trypsin for 30 min, and subsequently the cell
suspension was centrifuged for 2 min at 500 g (48C). Next, the
supernatant was discarded, and the cells were re-suspended in
50 ml of buffer and counted in a Bu ¨rker-cell chamber. Each
experiment was repeated twice, with each counting performed
in quadruplicate.
Patients and treatment
We retrospectively studied records from patients participating to
various prospective clinical trials on CPT-11 in which pharma-
co-kinetic monitoring was involved; the full clinical proﬁles are
documented elsewhere (Kehrer et al, 2000, 2001a, 2002). All
patients had a histologically or cytologically conﬁrmed malignant
solid tumour for which CPT-11 was considered to be a treatment
option. An adequate haematopoietic (white blood cell count
(WBC) 53.0610
9 l
71; absolute neutrophil count (ANC)
51.5610
9 l
71; and platelet count (PLT) 5100610
9 l
71), hepa-
tic and renal function at the time of study entry was required.
Eligibility criteria also included a World Health Organization
performance status of 0 or 1, and age between 18 and 70 years.
Before study entry, written informed consent was obtained from
all patients.
CPT-11 was provided by Aventis (Antony Cedex, France) as a
hydrochloride trihydrate salt in vials containing 40 or 100 mg,
dissolved in d-sorbitol and a lactic acid-sodium hydroxide buffer
system (pH 3.5–4.5) at a concentration of 20 mg ml
71. This solu-
tion was further diluted in 250 ml of sterile, isotonic sodium
chloride, prior to dosing. The drug was administered as a 90-
min continuous intravenous infusion at a dose of 350 mg m
72,
and each patient received prophylactic antiemetics including
ondansetron (8 mg) or granisetron (1 mg) and dexamethasone
(10 mg). In the ﬁrst course of treatment, patients did not receive
any other medication known to interfere with CPT-11 pharmaco-
kinetics.
Pharmacokinetic analysis
Blood samples for pharmacokinetic analysis were drawn from an
indwelling cannula from the arm opposite to that used for drug
infusion. These samples were collected in glass tubes containing
lithium heparin prior to infusion, at 0.5, and 1.5 h (end of in-
fusion) during infusion, and at 10, 20, and 30 min, and 1, 1.5,
2, 4, 5, 8.5, 24, 32, 48, 56, 190, 360, and 500 h after the end of
infusion. Blood samples were immediately centrifuged at 3000 g
for 10 min after collection to separate the blood cells and the plas-
ma fraction, and were stored at 7808C until analysis.
Concentrations of CPT-11 and its metabolite SN-38 were
determined by reversed-phase high-performance liquid chromato-
graphy with ﬂuorescence detection, as described in detail
elsewhere (De Bruijn et al, 1997). To determine SN-38 at low
femtomole levels, a more speciﬁc analytical method was used
(De Bruijn et al, 1999). Earlier pharmacokinetic ﬁndings showed
that total drug levels (i.e., the total of lactone and carboxylate
forms) of CPT-11 and SN-38 provided a consistent and accurate
reﬂection of the pharmacologically active lactone concentration
of both compounds with little variability (Sasaki et al, 1995).
Therefore, it was concluded that total drug monitoring of
CPT-11 and SN-38 could serve as an appropriate surrogate of
the respective lactone forms. For practical reasons, we only used
total drug forms for further analysis. Plasma concentration-time
data of CPT-11 and SN-38 were ﬁtted to a tri-exponential equa-
tion using the software package Siphar v4.0 (InnaPhase,
Philadelphia, PA, USA), based on previously described considera-
tions for model discrimination (Sparreboom et al, 1998).
Calculation of the area under the plasma concentration-time
curve (AUC) was based on integration from the tri-exponential
curve with extrapolation to inﬁnity. Extrapolated AUC values
of SN-38 were either based on a 56-h (AUC56 h) or a 500-hour
sampling-time period (AUC500 h).
Exposure-toxicity relationships
Haematological parameters of interest (i.e., those derived from
ANC, WBC and PLT) were determined before CPT-11 infusion
and on a twice weekly basis during the entire pharmacokinetic
sampling-time period, to enable a pharmacokinetic/pharmacody-
namic (PK/PD) evaluation. The pharmacodynamic endpoint for
establishment of the PK/PD relationships was determined in two
different ways. (i) First, prior to the PK/PD analysis, individual
toxicity data expressed as blood cell counts were plotted for each
patient in a concentration vs time proﬁle. The estimated area over
these curves (AOCtox), as well as the area under the curves
(AUCtox), was calculated by the linear-trapezoid method (Figure
2). The ratio AOCtox/(AOCtox+AUCtox), referred to as AOC, in
which the denominator represents the area described by the pre-
therapy toxicity value times the maximum pharmacokinetic
sampling time, was hypothesised to be a simple and accurate func-
tion of drug-related haematological toxicity (Gurney et al, 1998).
(ii) Second, drug-related haematological toxicities were evaluated
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Figure 1 Plasma concentration-time proﬁles of SN-38 in patients
treated with a 90-min i.v. infusion of CPT-11 (dose level 350 mg m
72).
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Figure 2 Example of an ANC-time pattern. The triangle represents the
nadir count. The horizontal line represents the baseline value of ANC.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 144–150by using the nadir count, which was measured to determine the
per cent decrease in haematopoietic cells as:
Percent decrease  pre-therapy value ÿ nadir count=
pre-therapy value100
To avoid confounding bias due to changes in haematological data
unrelated to treatment, patients showing extreme pre-infusion
haematological numbers (i.e., with ANC413.0610
9/liter
71) were
excluded in these calculations. Each of these two relative haemato-
logical-toxicity functions were ﬁtted to the AUC of SN-38 using a
sigmoidal maximum effect (Emax) model, based on a modiﬁed Hill
equation, as follows:
E  E0  Emax   AUCSNÿ38

=AUCSNÿ38

  CE50


In this equation, E0 is the minimum reduction possible, Emax is the
maximum response, CE50 is the AUC value of SN-38 predicted to
result in 50% of the maximum response, and g is the Hill constant,
which describes the sigmoidicity of the curve (Holford and Sheiner,
1981).
Pharmacokinetic-pharmacodynamic analysis was performed
using the software package Siphar v4.0, and weighted and
extended least squares techniques were used to estimate model
parameters. Model selection was guided by the decrease in the
objective function value (726log likelihood). The criteria to
assess the goodness of ﬁt of the models was based on: (i)
computation of the coefﬁcient of variation, deﬁned as the ratio
of the standard deviation computed using the variance-covariance
matrix and the parameter value, (ii) the Akaike information
criterion, and (iii) the correlation coefﬁcient and P-value of
the relationship.
Statistical considerations
All statistical calculations were performed using the Number
Cruncher Statistical System package v5.X (J.L. Hintze, East Kays-
ville, UT, USA) and/or the Siphar package. The level of
signiﬁcance was set at P50.05.
Limited sampling models (LSMs)
Patients were randomly entered in two groups, a training-data set
and a validation-data set containing up to 20 samples for each
individual patient, as has been described before (Mathijssen et al,
1999). A restricted block randomisation was performed as
described elsewhere (Altman, 1991) to keep the number of patients
close for both groups, and only one course of each patient was
taken to avoid bias as a result of potential cumulative effects and
to keep the observations independent.
Our goal was to predict the AUC of SN-38 adequately with a
minimum number of samples (1 to 3). Moreover, these samples
should be taken at the most convenient time-points for practical
reasons. The ﬁrst step in the model development consisted of
univariate linear-regression analysis to determine the best single-
sample time points from the training data set. Next, we performed
a stepwise (forward) multivariate linear-regression analysis using
the optimal single sampling-time points to describe the association
between SN-38 concentrations at multiple time points and its
corresponding AUC. The Pearson’s coefﬁcient (r), root mean-
square error (RMSE), and mean-predictive error (MPE), which
describe correlation, precision and bias, respectively, were calcu-
lated to determine the best LSMs. The usefulness of the models
was evaluated in the training data set, by comparing AUC values
determined using the full data with AUC values predicted by the
LSMs.
RESULTS
In vitro analysis of SN-38–induced cytotoxicity
The growth-inhibitory potential of low SN-38 concentrations was
evaluated in vitro against several cell lines using a 3-week continu-
ous-exposure period. Clear manifestation of growth-inhibiting
effects were seen at SN-38 concentrations of 100 pM, 1.00 nM
and 10.0 nM in the IGROV cell lines, with the number of remain-
ing viable cells being reduced by 46+8.7%, 77+10.4%, and
499.9%, respectively, as compared to untreated controls (Figure
3). At these concentrations, 34+5.9%, 73+4.0% and 98+0.2%
growth inhibition, respectively, was seen in the H226 cells, relative
to their controls. As the doubling time of the Caco-2 was shorter
than that of the IGROV cells, data could not be obtained for the
entire 3-week period in the Caco-2 cell line. Nonetheless, the data
suggest overall that the low circulating concentrations of SN-38
determined previously in patients receiving CPT-11 at a dose of
350 mg m
72 induce substantial inhibition of cancer cell growth,
in spite of evident concerns in extrapolating data from in vitro
experiments to the clinical situation.
Patient population
A total of 26 patients, predominantly suffering from colorectal
cancer, were entered onto the current trial (Table 1). All patients
received a single-agent regimen with CPT-11 in the ﬁrst treatment
course at a dose of 350 mg m
72. One course was excluded because
of extreme pre-treatment values for haematological parameters
(i.e., ANC value greater than 13.0610
9 l
71), making a total of
25 courses assessable for PK/PD analysis.
Pharmacokinetics and pharmacodynamics
The two groups of SN-38 AUCs based on short (up to 56 h) and
prolonged sampling (up to 500 h), respectively, were highly corre-
lated (r
2=0.79). However, as shown in Figure 4, all AUC values
calculated using the short sampling-time period substantially
underestimated the true AUC, albeit with huge variation (7 up
to 81%). The mean dose over AUC ratio for SN-38 based on
prolonged sampling was 860+410 L h
71 in this group of patients,
and was 1400+890 L h
71 when based on short sampling.
The parameter estimates for the different pharmacodynamic
models are shown in Figure 5. Preliminary results demonstrated
that separate estimation of the observed maximum effect did
improve the ﬁts, and that optimal results were obtained with a
model ﬁtted to the data using weighted least squares (weighting
factor, 1/y) and the Powell minimization algorithm. Data sets
based on short and prolonged sampling were both plotted sepa-
rately against individual values of ANC, WBC and PLT applying
the ratio AOCtox/(AOCtox+AUCtox) and the per cent decrease in
blood cell counts, using the Emax-model (Gianni et al, 1995;
Ohtsu et al, 1995). The kinetic parameters predicted to result in
half of the maximum response showed a substantial degree of
interindividual variability, and were poorly estimated in some
models, presumably because of the small number of patients.
The exposure-neutropenia relationship was best described with
the model based on the 500-h sampling-time period and the ratio
AOCtox/(AOCtox+AUCtox) (Figure 5B), although no signiﬁcant
improvement of the ﬁt was obtained as compared to the relation-
ship based on the short sampling time period (Figure 5A). In the
optimal model, the following model parameters were observed:
CE50=460+82.9 ng h ml
71, g=2.22+1.55, P=0.0001 and r=0.77.
With the use of the per cent decrease in ANC at nadir as phar-
macodynamic measure, the ﬁts were worse than those based on
AOC. The disparity in the data of ratio AOCANC/(AOCANC+AU-
CANC) and per cent decrease in ANC suggests that PD analysis
based on per cent decrease in ANC is not sufﬁciently accurate
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In contrast to ANC, no correlations with PK were observed for
WBC and PLT.
Limited-sampling models
We developed a new limited-sampling model (LSM) for determi-
nation of SN-38 AUC500 h using one to three samples taken after
drug administration, taking into account feasibility and usefulness
in a routine clinical setting. There were no signiﬁcant differences
in patient characteristics between the training and validation data
set. The same 26 patients were included in this analysis, and in
both groups 13 patients were entered (six females and seven
males in both cases). The median age in the training set was
53 years (range, 37 to 71 years), vs 54 years (range, 42 to 71
years) in the validation set. Results of a univariate-linear regres-
sion analysis of SN-38 concentrations at each sample time point
and the corresponding AUC showed correlation coefﬁcients
ranging from 0.08 to 0.82 in the training set (Table 2). Multi-
ple-regression analysis, based on one or two additional time
point led to signiﬁcantly improved correlation coefﬁcients. Based
on a variety of considerations, including low values for RMSE
and MPE with high correlation coefﬁcients, the optimal LSM
was a bivariate model containing concentration data at two time
points
AUCSNÿ38nghmlÿ1 6:588  C2:5h 146:4  C49:5h15:53
where C2.5 h and C49.5 h represent plasma concentrations of SN-38
(in ng ml
71) at 2.5 h after the start of infusion (1 h post-infusion)
and 49.5 h (48 h post-infusion), respectively. In both the training
set and validation sets, this model showed little bias (MPE,
0.33% and 0.76%) and excellent precision (RMSE, 4.9% and
9.1%), with correlation coefﬁcients of 0.99 and 0.96, respectively
(Figure 6).
Trivariate models were also evaluated using the clinically most
optimal sample-time points (i.e. 1, 190 and 360 h post-infusion).
Unfortunately, the predictive performance of this model appeared
to be worse (validation set: MPE=1.6%; RMSE=18%; r
2=0.83),
despite acceptable training set statistics (MPE=0.62%; RMSE=9.5%;
r
2=0.95).
DISCUSSION
This study shows that the prolonged exposure at low circulating
concentrations of the pharmacologically active CPT-11 metabolite,
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Figure 3 Cell-growth vs time curves for the IGROV (A), Caco-2 (B), and H226 (C) cell lines, incubated with medium containing 100 pM, 1.00 nM or
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Table 1 Patient characteristics for PK/PD evaluation
Characteristic
Total number of patients 26
Total number of courses 38
Assessable courses 25
Age [years (range)] 54
a (37–71)
Sex (male/female) 12/14
Primary tumour site:
Colorectal 24
Cervix 1
Unknown primary site 1
aResults expressed as median value.
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Figure 4 Relationship between calculated SN-38 AUCs, based on 500-h
sampling and 56-h sampling respectively. (n=38). The solid line represents
the line of identity (y=x).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 144–150SN-38, in plasma of cancer patients after a single dose has impor-
tant cytotoxic potential in vitro and therewith may have clinical
relevance toward SN-38-induced toxicity and antitumour activity.
In our in vitro experiments we exposed several cancer cell lines
to SN-38 concentrations, which were known to be circulating in
plasma for up to 3 weeks after a 90-min i.v. infusion of CPT-11
at a dose of 350 mg m
72. After a 3-week incubation period in
the presence of SN-38 at concentrations of 100 pM, 1.00 nM and
10.0 nM, signiﬁcantly reduced tumour growth was observed as
compared to untreated cells, suggesting signiﬁcant cytotoxic activ-
ity, even at these low drug levels. Using pharmacokinetic data from
26 patients treated with CPT-11, with sampling up to 500 h after
drug administration, PK/PD relationships were evaluated between
systemic exposure (AUC) to SN-38 and the per cent decrease in
ANC at nadir or by taking the entire time course of ANC into
account (AOC), using a modiﬁed Hill function (sigmoidal Emax
model). Taking into consideration the entire time course of SN-
38 concentrations (AUC500 h), the most optimal relationships were
observed for the AOCs. These data not only emphasise the need to
apply appropriate PK/PD models with sufﬁcient sampling-time
points for the accurate estimation of complete concentration-time
proﬁles, but also has direct clinical relevance in view of the fact
that relationships between drug exposure and effect (i.e., toxicity
and efﬁcacy) were previously poorly deﬁned (Mathijssen et al,
2001).
We have shown earlier that the use of an extended sample-
collection period of 500 h led to terminal disposition half-life
and AUC estimates for SN-38 after CPT-11 administration of
47+7.9 h and 2.0+0.79 mM h, respectively (Kehrer et al, 2000),
both representing a two-fold increase as compared to earlier
reported estimates. As an explanation for this phenomenon, we
previously observed a substantial formation of SN-38 from CPT-
11 and the cytochrome P-450 3A4-mediated metabolite, NPC, by
plasma carboxylesterases. In addition, transport studies in Caco-2
cell monolayers indicated that SN-38 could cross the membrane
from the apical to the basolateral side, indicating the potential
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(Kehrer et al, 2000). More recently, we also noted extensive parti-
tioning of CPT-11 in erythrocytes resulting in prolonged
association of the parent drug in the central blood compartment
(Mathijssen et al, 2002b). Regardless of the exact underlying causes
for the prolonged SN-38 circulation, the fact that low circulating
levels of SN-38 demonstrate profound cytotoxic potential indicates
the need to not take an oversimpliﬁed view when modelling drug-
induced haematological toxicity.
Pharmacokinetic information on the concentration-time proﬁles
has previously been combined with efﬁcacy-toxicity data to form
PK/PD models for drugs in a wide variety of therapeutic areas.
The most common type of this kind of PK/PD model is one in
which a summary measure of exposure, such as AUC, is related
to the principal side effect of the treatment, in this case haemato-
logical toxicity, for which singly measured nadir counts are usually
employed. However, experimental evidence suggests that informa-
tion on an entire time course of changes in blood cell counts is
more important than the nadir count. For example, it has been
demonstrated that patients with prolonged neutropenia have a
greater risk of infection than patients who have the same nadir
count with rapid recovery. Therefore, we hypothesised that using
data from the entire time course of neutropenia after CPT-11 treat-
ment would provide useful information. Thus, we analysed our
data using two different types of analysis (per cent decrease in toxi-
city at nadir and a measure of time course (AOC)) using two
different variables based on AUC calculated using 56-h or 500-h
sampling periods, with those based on AOC showing superiority
for prediction of haematological toxicity. For both PD parameters,
the quantity of available data is positively correlated with the qual-
ity (accuracy) of the determined outcome variables. Thus, at least
several data points are required for an accurate estimate of the
nadir count. In our current study, a rich data set was available with
haematological toxicity data, which might explain the moderate
predictive performance of the PK/PD relationship using (assumed)
nadir counts. Clinically even more important PD parameters than
the just mentioned parameters may be (i) the time period during
which the neutrophil count remains below a certain level (for
instance 4610
9 cells l
71) or (ii) the area between the curve of time
vs leukocyte count and the line representing a cell count of
4610
9 cells l
71 (Minami et al, 2001). Also in our current study,
this area was shown to demonstrate the best correlation of all
tested PK/PD combinations. In order to further optimise PK/PD
relationships, a population model for CPT-11-induced neutropenia
by modelling the full time course of haematological toxicity is
currently being developed, as done previously for paclitaxel and
etoposide (Karlsson et al, 1998; Minami et al, 1998, 2001).
Some clinical implications from the data presented in this study,
particularly with respect to considerations of treatment schedule,
are easily envisaged. Regarding administration regimens of CPT-
11 used in cancer patients, it is particularly noteworthy that differ-
ent schedules are being used in Europe (350 mg m
72 once every 3
weeks), the USA (125 mg m
72 weekly for 4 or 6 weeks) and Japan
(100 mg m
72 every week, Kehrer et al, 2001b). Furthermore, there
is a current trend for the use of protracted intravenous or oral
dosing regimens of CPT-11 using daily drug administration (Kehrer
et al, 2001b), based on earlier clinical experience with camptothecin
analogues with relatively short terminal disposition half-lives, such
as topotecan. However, the unique pharmacokinetic behaviour of
SN-38, coupled to our current pharmacodynamic observations,
suggests that a single administration of CPT-11 repeated every third
week is the preferred regimen, and that increased frequency of
administration may result in drug accumulation.
Obviously, the clinical applicability of SN-38 AUC as PK
parameter predicting toxicity would increase by the availability of
accurate and predictive LSMs. Earlier developed models for the
determination of SN-38 total AUC were only useful for the
estimation of AUC models up to 24 or 56 h (Mathijssen et al,
1999). Therefore, a new limited-sampling model (LSM) was
developed for determination of SN-38 AUC500 h using only two
timed samples: AUC500 h (ng h ml
71)=(6.5886C2.5 h)+(146.46
C49.5 h)+15.53, where C2.5 h and C49.5 h are plasma concentrations
at 2.5 and 49.5 h after start of CPT-11 infusion, respectively. The
model was shown to be precise (RMSE=4.9%) with no demonstra-
tion of any bias (MPE=0.33%). This model enables us to perform
PK studies in a very efﬁcient manner, and it is less expensive and
might therefore be applicable to large-scale investigations. For
example, PK sampling might be performed easily in an outpatient
setting. In addition, the use of this LSM may open up historic
databases for a re-evaluation, or at least provide prospective studies
to obtain information about SN-38-mediated (haematological)
toxicity in cancer patients treated with CPT-11. For the determina-
tion of SN-38 AUC, this model is currently being implemented in a
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Table 2 Univariate correlation betwen SN-38 total concentrations at
each sampled time point (after the start of infusion) and its corresponding
AUC in training-data set patients
Time point (h) r
a Number of patients
0.50 0.25 13
1.50 0.14 13
1.67 0.14 13
1.83 0.08 12
2.00 0.22 13
2.50 0.35 13
3.00 0.22 12
3.50 0.09 10
5.50 0.25 13
6.50 0.15 12
10.0 0.24 13
25.5 0.48 13
33.5 0.49 11
49.5 0.68 11
57.5 0.82 7
191.5 0.54 13
361.5 0.54 10
501.5 0.34 10
ar: Pearson’s correlation coefﬁcient.
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Figure 6 Correlation between the observed AUC from a linear three-
compartment model and the predicted AUC from the LSM for SN-38
total. Closed symbols represent training set data; open symbols represent
validation set data. The solid line represents the line of identity (y=x).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 144–150multi-institutional clinical trial with CPT-11 administered at a dose
level of 350 mg m
72 in the presence or absence of the aminoglyco-
side antibiotic, neomycin.
In conclusion, we have shown that the prolonged circulation of
SN-38 at low concentrations following CPT-11 administration has
clinical implications, and resulted in altered exposure-toxicity rela-
tionships. This information, coupled to the prospective
implementation of the newly developed LSM, may be of impor-
tance for future individualisation of drug therapy in order to
avoid excessive toxicity.
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